View Related Items
Category 6 - PATHOLOGY SERVICES
PN.7.22
DPYD genotyping to diagnose or predict fluoropyrimidine-induced toxicity
The list of gene variants analysed should be selected in line with current clinical guidelines, such as the eviQ guidelines, and should include direct detection of at least the following variants:
• NM_000110.4(DPYD):c.1905+1G>A
• NM_000110.4(DPYD):c.1679T>G
• NM_000110.4(DPYD):c.2846A>T
• NM_000110.4(DPYD):c.1129-5923C>G
Related Items: 73322
Related Items
Category 6 - PATHOLOGY SERVICES
73322 - Additional Information
Genetic testing in the DPYD gene to diagnose or predict fluoropyrimidine-induced toxicity in a patient, if:
(a) the service is requested by a specialist or consultant physician; and
(b) the service is rendered before, during or after systemic administration of chemotherapy or radio-sensitisation, with a fluoropyrimidine, to the patient; and
(c) genotyping is performed to detect DPYD variants linked to reduced or absent dihydropyrimidine dehydrogenase activity
Applicable once per lifetime
Fee: $182.00 Benefit: 75% = $136.50 85% = $154.70
(See para PN.7.22 of explanatory notes to this Category)
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change